Earnings Call Intelligence Subscribe
Home › Call Sheets › XYL › Q4'25
Call sheet · Q4'25

Xylem (XYL)

Q4'25 earnings call · held February 10, 2026 · compared with the Q3'25 call · management-credibility review
11/12
Disclosure score
4 medium, 3 low flags
Financial quality
Bottom line
The sleeper story is treatment margins exploding 510 bps as Xylem's biggest backlog business finally implements 80/20 - this division alone could drive significant segment-level margin expansion through 2026. Everyone will focus on the low-end revenue guide, but Pine called 2026 the 'peak of purposeful walkaways' while maintaining 70-110 bps margin expansion - they're trading growth for quality at exactly the right moment. The binding constraint is MCS project timing variability replacing the post-COVID backlog cushion that smoothed quarterly lumpiness. Pine's most revealing quote: 'project timing has been more variable and less predictable than we have experienced over the last few years.' My view changes if treatment margins don't accelerate or if MCS project delays signal broader utility CapEx weakness rather than just timing.

The 30-second version

  • The sleeper story: Water treatment margins explode 510 basis points as 80/20 finally hits the biggest backlog business
  • Revenue walkaway acceleration creates a 2026 growth ceiling that's actually a margin floor
  • MCS project timing gets more 'variable and less predictable' as post-COVID backlog normalization ends

What changed this quarter

MetricQ3'25Q4'25Change
Total Revenue$2.2B (+7% YoY in Q3)$2.4B (+4% YoY in Q4)Growth decelerated 300 bps but beat tough comp
EBITDA Margin23.0% (+200 bps YoY in Q3)23.2% (+220 bps YoY in Q4)Record quarterly margin, 20 bps sequential gain
EPS$1.37 (+23% YoY in Q3)$1.42 (+20% YoY in Q4)Growth rate cooled but still strong double-digit
MCS Revenue11% organic growth in Q310% organic growth in Q4Stayed in double-digits despite tough comp
Water Infrastructure EBITDA Margin24.4% (+400 bps YoY in Q3)510 bps expansion YoY in Q4Acceleration of margin expansion
MCS Backlog$1.5B in Q3$1.4B in Q4Down $100M as normalization continues
Orders Growth-2% organic in Q3+7% organic in Q4Sharp reversal led by MCS +22%
China Revenue ImpactDouble-digit declines mentionedAlmost 30% decline in Water InfrastructureAccelerating deterioration
Free Cash FlowDown modestly YTD in Q3Down 2% YTD full yearDeterioration as expected from projects and restructuring
Net Debt to EBITDA0.4x in Q30.2x in Q4Balance sheet strengthened further

Accountability tracked

8 new promises made4 narrative shifts flagged7 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full XYL Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.